InsiderSignal.AI

InsiderSignal.ai

STOK - Stoke Therapeutics, Inc.

Insider Sale by Krainer Adrian R. (Dir)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

5 days ago, Krainer Adrian R., serving as Dir at Stoke Therapeutics, Inc. (STOK), sold 33,243 shares at $39.74 per share, for a total transaction value of $1,320,964.00. Following this transaction, Krainer Adrian R. now holds 283,302 shares of STOK.

This sale represents a 11.00% decrease in Krainer Adrian R.'s stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Tuesday, March 10, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, March 12, 2026, 2 days after the trade was made.

Stoke Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Krainer Adrian R.

Dir

Adrian R. Krainer, Ph.D., is a Uruguayan-American biochemist and molecular geneticist renowned for his pioneering research on RNA splicing.[[3]](https://en.wikipedia.org/wiki/Adrian_Krainer_(scientist))[[1]](https://www.stoketherapeutics.com/about-stoke/leadership/adrian-krainer/) He holds the St. Giles Foundation Professorship and serves as Deputy Director of Research at the Cold Spring Harbor Laboratory (CSHL) Cancer Center, where he has been faculty since 1989.[[1]](https://www.stoketherapeutics.com/about-stoke/leadership/adrian-krainer/)[[2]](https://www.nasonline.org/directory-entry/adrian-r-krainer-jpoemg/)[[5]](https://www.ceitec.eu/life-after-phd-with-adrian-and-kate-krainer/a3898) Krainer earned his BA in Biochemistry from Columbia University and PhD from Harvard University.[[5]](https://www.ceitec.eu/life-after-phd-with-adrian-and-kate-krainer/a3898) His over three decades of research directly led to the invention and development of Spinraza™ (nusinersen), the first approved therapeutic correcting a splicing defect for spinal muscular atrophy.[[1]](https://www.stoketherapeutics.com/about-stoke/leadership/adrian-krainer/)[[5]](https://www.ceitec.eu/life-after-phd-with-adrian-and-kate-krainer/a3898) Krainer is a co-founder and Director of Stoke Therapeutics, Inc. (STOK), a biotechnology company focused on RNA-based therapies for genetic diseases using the proprietary TANGO platform targeting pre-mRNA splicing.[[1]](https://www.stoketherapeutics.com/about-stoke/leadership/adrian-krainer/)[[4]](https://www.stoketherapeutics.com/about-stoke/founders/)[[3]](https://en.wikipedia.org/wiki/Adrian_Krainer_(scientist)) He has received prestigious awards including the 2021 Wolf Prize in Medicine, 2019 Breakthrough Prize in Life Sciences, 2019 RNA Society Lifetime Achievement Award, and memberships in the National Academy of Sciences, National Academy of Medicine, American Academy of Arts and Sciences, and National Academy of Inventors.[[1]](https://www.stoketherapeutics.com/about-stoke/leadership/adrian-krainer/)[[2]](https://www.nasonline.org/directory-entry/adrian-r-krainer-jpoemg/)[[5]](https://www.ceitec.eu/life-after-phd-with-adrian-and-kate-krainer/a3898) Recently, on March 2, 2026, Krainer sold 7,229 shares of STOK under a Rule 10b5-1 plan, retaining 316,545 shares.[[6]](https://www.stocktitan.net/sec-filings/STOK/form-4-stoke-therapeutics-inc-insider-trading-activity-80d5c5d8e02a.html)[[7]](https://www.gurufocus.com/news/8679125/insider-sell-adrian-krainer-sells-7229-shares-of-stoke-therapeutics-inc-stok)

View full insider profile →

Trade Price

$39.74

Quantity

33,243

Total Value

$1,320,964.00

Shares Owned

283,302

Trade Date

Tuesday, March 10, 2026

5 days ago

SEC Filing Date

Thursday, March 12, 2026

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

About Stoke Therapeutics, Inc.

Company Overview

No company information available
View news mentioning STOK

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4724452

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime